GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » Short-Term Debt & Capital Lease Obligation

Paion Ag (Paion Ag) Short-Term Debt & Capital Lease Obligation : $3.00 Mil (As of Jun. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Paion Ag Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Paion Ag's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $3.00 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Paion Ag's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $20.02 Mil.

Paion Ag Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Paion Ag's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paion Ag Short-Term Debt & Capital Lease Obligation Chart

Paion Ag Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Short-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 4.90 0.01 1.63 1.52

Paion Ag Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Short-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.78 1.63 1.52 1.52 3.00

Paion Ag Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Paion Ag Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Paion Ag's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Paion Ag (Paion Ag) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » Short-Term Debt & Capital Lease Obligation
Comparable Companies
FRA:SPB HAM:GWK3 STU:DWB FRA:BBI HAM:TLG ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX HKSE:03692 TSE:4507 NSE:DIVISLAB BOM:500124 BOM:532321
Traded in Other Exchanges
PA8:Germany
Address
Heussstrasse 25, Aachen, DEU, 52078
Website
https://www.paion.com
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.